-
Mashup Score: 0Trastuzumab emtansine improves OS in HER2+ breast cancer, phase III study shows - The Cancer Letter - 1 day(s) ago
In patients with high-risk HER2-positive breast cancer, post-surgery, or adjuvant, treatment with trastuzumab emtansine, also referred to as T-DM1) reduced the long-term risk of death or invasive disease by 46% and improved survival compared to trastuzumab alone, according to the final results of the phase III KATHERINE clinical trial led by researchers from the University […]
Source: cancerletter.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 2FDA and OHRP draft guidance aims to improve ethics of tissue biopsies in clinical trials - The Cancer Letter - 1 day(s) ago
The U.S. Food and Drug Administration and the U.S. Department of Health and Human Services Office of Human Research Protections issued Draft Guidance on the inclusion of tissue biopsies in clinical trials. To access this subscriber-only content please log in or subscribe.If your institution has a site license, log in with IP-login or register for […]
Source: cancerletter.comCategories: General Medicine News, Oncologists1Tweet-
FDA and OHRP draft guidance aims to improve ethics of tissue biopsies in clinical trials. Guest editorial by @ASCO leaders. https://t.co/PDH6ErXtI3 https://t.co/0PPZgQKF7x
-
-
Mashup Score: 1NCCN publishes patient resource on genetic testing to guide patient decisionmaking - The Cancer Letter - 2 day(s) ago
The National Comprehensive Cancer Network published its first patient resource aimed at informing people about the latest recommendations around hereditary and familial cancer risk. The document provides guidance on testing for inherited genetic mutations that can raise the risk of cancer. To access this subscriber-only content please log in or subscribe.If your institution has a […]
Source: cancerletter.comCategories: General Medicine News, Oncologists1Tweet-
.@NCCN publishes patient resource on genetic testing to guide patient decisionmaking https://t.co/kmqDDHj1cQ https://t.co/1SmF2ibLXj
-
-
Mashup Score: 0FDA approves sotorasib + panitumumab for KRAS G12C-mutated colorectal cancer - The Cancer Letter - 2 day(s) ago
FDA approved sotorasib (Lumakras) with panitumumab (Vectibix) for adult patients with KRAS G12C-mutated metastatic colorectal cancer, as determined by an FDA-approved test, who have received prior fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. To access this subscriber-only content please log in or subscribe.If your institution has a site license, log in with IP-login or register for a […]
Source: cancerletter.comCategories: General Medicine News, Oncologists1Tweet-
FDA approves sotorasib + panitumumab (@AmgenOncology) for KRAS G12C-mutated colorectal cancer. https://t.co/TKLNrg7JYS
-
-
Mashup Score: 12Cedars-Sinai Cancer’s model of care ensured patient care amid wildfires - The Cancer Letter - 2 day(s) ago
Over the past five years, Cedars-Sinai Cancer has built an integrated, regional system designed to provide cancer care close to where patients live and work. This model of care, directed by an academic medical center to patients at the community level, proved to be the best possible approach to supporting patients in our 11-million-person catchment […]
Source: cancerletter.comCategories: General Medicine News, Oncologists1Tweet-
Cedars-Sinai Cancer’s model of care ensured patient care amid wildfires, write @Dan_Theodorescu, Robert Figlin, @DrHowardSandler, and Joan August https://t.co/2cc2GWSym6 https://t.co/EjWQGxhPwh
-
-
Mashup Score: 0NCCN guidelines updated to include ctDNA-MRD testing recommendation for B-cell lymphoma - The Cancer Letter - 2 day(s) ago
The National Comprehensive Cancer Network included circulating tumor DNA testing in their Clinical Practice Guidelines in Oncology for diffuse large B-cell lymphoma. This marks the first-ever inclusion of ctDNA-MRD testing in these guidelines, representing a significant advancement in lymphoma patient care. To access this subscriber-only content please log in or subscribe.If your institution has a […]
Source: cancerletter.comCategories: General Medicine News, Oncologists1Tweet-
.@NCCN guidelines updated to include ctDNA-MRD testing recommendation for B-cell lymphoma. https://t.co/7evmwqk1Bx
-
-
Mashup Score: 4ACS report: Cancer mortality continues to drop despite rising incidence in women - The Cancer Letter - 2 day(s) ago
Despite steady progress in reducing overall cancer mortality rates, cancer incidence in women is rising, according to the American Cancer Society’s “Cancer Statistics, 2025” report. Incidence rates in women 50-64 years of age have surpassed those in men, and rates in women under 50 are now 82% higher than their male counterparts, up from 51% […]
Source: cancerletter.comCategories: General Medicine News, Oncologists1Tweet-
.@AmericanCancer report: Cancer mortality continues to drop despite rising incidence in women https://t.co/Lrvh60Lh9J https://t.co/IGbuWUNsrx
-
-
Mashup Score: 4
The American Society of Clinical Oncology elected Elizabeth A. Mittendorf to lead as its president beginning in June 2026. Mittendorf, a long-time ASCO member and volunteer, will take office as president-elect immediately following the ASCO Annual Business Meeting in Chicago on June 2. To access this subscriber-only content please log in or subscribe.If your institution […]
Source: cancerletter.comCategories: General Medicine News, Oncologists1Tweet-
Elizabeth Mittendorf elected @ASCO president for 2026-2027 term. https://t.co/nFjyEZW7zU https://t.co/M1B5IsmjFr
-
-
Mashup Score: 27
W. Kimryn Rathmell has stepped down as NCI director, opting to hand her resignation to the Biden administration over facing the uncertainties that Trump and his team are expected to usher in starting next week. To access this subscriber-only content please log in or subscribe.If your institution has a site license, log in with IP-login […]
Source: cancerletter.comCategories: General Medicine News, Oncologists1Tweet-
Rathmell steps down at NCI as Trump team considers candidates to replace her. Wafik El-Deiry, Harvey Risch have been interviewed. https://t.co/0Vapqj8un5
-
-
Mashup Score: 1NCCN publishes patient resource on genetic testing to guide patient decisionmaking - The Cancer Letter - 5 day(s) ago
The National Comprehensive Cancer Network published its first patient resource aimed at informing people about the latest recommendations around hereditary and familial cancer risk. The document provides guidance on testing for inherited genetic mutations that can raise the risk of cancer. To access this subscriber-only content please log in or subscribe.If your institution has a […]
Source: cancerletter.comCategories: General Medicine News, Oncologists1Tweet-
.@NCCN publishes patient resource on genetic testing to guide patient decisionmaking https://t.co/kmqDDHj1cQ https://t.co/1SmF2ibLXj
-
Trastuzumab emtansine improves OS in HER2+ breast cancer, phase III study (led by @pitt_medicine & @UPMCHillmanCC) shows. https://t.co/1sZ29z0kut